Edition:
United States

Cesca Therapeutics Inc (KOOL.PH)

KOOL.PH on Philadelphia Stock Exchange

3.13USD
3 May 2017
Change (% chg)

-- (--)
Prev Close
$3.13
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
444
52-wk High
$7.36
52-wk Low
$2.75

Latest Key Developments (Source: Significant Developments)

Cesca Therapeutics Q3 loss per share $0.21
Thursday, 11 May 2017 04:16pm EDT 

May 11 (Reuters) - Cesca Therapeutics Inc ::Cesca Therapeutics announces fiscal third quarter and nine month 2017 financial and operating results and provides corporate update.Q3 revenue $3.3 million versus $2.8 million.Q3 loss per share $0.21.  Full Article

Cesca Therapeutics announces closing of $5 mln revolving line of credit
Monday, 13 Mar 2017 06:00am EDT 

Cesca Therapeutics Inc - : Cesca Therapeutics announces closing of $5 million revolving line of credit . Has set-up a wholly-owned subsidiary, Thermogenesis Corp, to separately own and operate its device business . Clinical development activities will remain with cesca, parent company ."Our goal is to make thermogenesis cash-flow neutral within next 12 months".  Full Article

Cesca Therapeutics Q2 revenue rose 22 percent to $4.0 mln
Monday, 13 Feb 2017 04:05pm EST 

Cesca Therapeutics Inc : Cesca therapeutics reports second quarter fiscal 2017 financial results and provides business update . Q2 revenue rose 22 percent to $4.0 million .Says net loss was $3.4 million for three months ended december 31, 2016.  Full Article

Cesca Therapeutics files for resale of up to 950,000 common shares
Friday, 20 Jan 2017 02:09pm EST 

Cesca Therapeutics Inc : Files for resale of up to 950,000 shares of co's common stock by the selling stockholders - sec filing .Co will not receive any of the proceeds from the sale of the shares by the selling stockholders.  Full Article

Cesca Therapeutics reports first quarter fiscal 2017 results and provides business update
Thursday, 17 Nov 2016 04:05pm EST 

Cesca Therapeutics Inc : Cesca Therapeutics reports first quarter fiscal 2017 results and provides business update . Cesca Therapeutics Inc says net loss was $22.4 million for three months ended September 30, 2016, compared to $3.4 million for corresponding fiscal 2016 period .Q1 revenue $3.8 million versus $2.8 million.  Full Article

Empery Asset Management LP reports 5.43 pct passive stake in Cesca Therapeutics
Monday, 15 Aug 2016 05:19pm EDT 

Cesca Therapeutics Inc : Empery Asset Management, LP reports 5.43 pct passive stake in Cesca Therapeutics as of August 4, 2016 - SEC Filing Source - http://bit.ly/2bl8rAM Further company coverage: [KOOL.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Cesca Therapeutics announces pricing of $2.5 mln registered direct offering
Thursday, 4 Aug 2016 09:08am EDT 

Cesca Therapeutics Inc: Cesca Therapeutics announces pricing of $2.5 million registered direct offering .To purchase 600,000 shares of common stock at a purchase price per share of $4.10.  Full Article

Cesca Therapeutics files for mixed shelf of up to $30 mln
Wednesday, 29 Jun 2016 05:21pm EDT 

Cesca Therapeutics Inc :Files for mixed shelf of up to $30.0 million - SEC filing.  Full Article

Cesca Therapeutics submits investigational device exemption supplement for Surgwerks CLI pivotal trial
Wednesday, 1 Jun 2016 11:15am EDT 

Cesca Therapeutics Inc: Cesca therapeutics submits investigational device exemption supplement for Surgwerks CLI pivotal trial .Expects FDA to submit its response to IDE supplement within 30 days of submission.  Full Article

Cesca Therapeutics Q3 revenue $2.8 million
Thursday, 12 May 2016 04:37pm EDT 

Cesca Therapeutics Inc : Says net loss from operations for quarter ended march 31, 2016 was $2.7 million compared to $4.8 million . Expects to submit an ide supplement to fda at end of month detailing a range of changes to pivotal cli trial design . Cesca therapeutics reports third quarter fiscal 2016 results and provides business update .Q3 revenue $2.8 million versus $4.0 million.  Full Article

More From Around the Web

BRIEF-Cesca Therapeutics Q3 loss per share $0.21

* Cesca Therapeutics announces fiscal third quarter and nine month 2017 financial and operating results and provides corporate update